Taking Control: Emerging Issues in Pain ... - Pharmacy Times
Taking Control: Emerging Issues in Pain ... - Pharmacy Times
Taking Control: Emerging Issues in Pain ... - Pharmacy Times
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Addiction or Chronic Pa<strong>in</strong><br />
Source of Divert<strong>in</strong>g Drugs<br />
Addiction<br />
• Medication use<br />
• Out of control<br />
• Impairs quality of life<br />
• Cont<strong>in</strong>ues despite adverse effects<br />
• Unaware/<strong>in</strong> denial of any problems<br />
• Doesn’t follow agreement<br />
• Doesn’t have leftover med<br />
• Loses prescriptions<br />
• Always has a story<br />
Chronic Pa<strong>in</strong><br />
• Medication use<br />
• Not out of control<br />
• Improves quality of life<br />
• Desire to decrease meds with<br />
adverse effects<br />
• Concerned about physical<br />
problem<br />
• Follows agreements<br />
• Frequently has leftover meds<br />
• Forged and Altered Prescriptions<br />
• “Doctor Shoppers”<br />
• Prescribers/ Dispensers of Rx Drugs<br />
• Theft (Health Facility and Other)<br />
• Package Theft/ Diversion (UPS/DHL/FedEx)<br />
• Internet<br />
• <strong>Pharmacy</strong> Robbery & Burglary<br />
• International Smuggl<strong>in</strong>g<br />
Fishman S. Responsible Opioid Prescrib<strong>in</strong>g. 2nd ed. Wash<strong>in</strong>gton DC, Waterford Life Science, 2012:30.<br />
Top RX Drug Abuse<br />
• Hydrocodone (Lortab, Vicod<strong>in</strong>, Lorcet) $6-$8<br />
• Vicod<strong>in</strong>: #1 prescribed drug (2006-2010)<br />
• Oxycodone (Percocet, Percodan) $6-$8<br />
• Oxycodone IR- $1 mg<br />
• Oxymorphone (Opana/Opana ER) $10- $40<br />
• Methylphenidate (Rital<strong>in</strong>) $10- $12<br />
• Hydromorphone (Dilaudid) 4 mg - $60<br />
• Alprazolam (Xanax) $3<br />
• Fentanyl (Duragesic/ Actiq) $8- $40<br />
• Methadone ($10- $40 per dose)<br />
The Growth of<br />
Prescription Monitor<strong>in</strong>g Programs<br />
2003<br />
• 14 states had<br />
monitor<strong>in</strong>g programs<br />
• 36 states had no<br />
prescription monitor<strong>in</strong>g<br />
programs<br />
Data collected from http://www.pmpalliance.org/content/data<br />
2012<br />
• 41 states had<br />
prescription drug<br />
monitor<strong>in</strong>g programs<br />
• 9 states had no<br />
monitor<strong>in</strong>g program<br />
Management of Risk:<br />
A “Package Deal”<br />
Screen<strong>in</strong>g for<br />
Substance-Abuse Potential<br />
• Screen<strong>in</strong>g & risk stratification<br />
• Compliance monitor<strong>in</strong>g:<br />
• Ur<strong>in</strong>e screen<strong>in</strong>g<br />
• Pill/patch counts<br />
• Education on drug storage & shar<strong>in</strong>g<br />
• Psychotherapy<br />
• Highly “structured” approaches<br />
• Abuse-deterrent formulations<br />
Predictive of Aberrant Behavior<br />
Alcohol consumption<br />
Drug use<br />
Smok<strong>in</strong>g<br />
Age<br />
Use Caution With:<br />
Men who dr<strong>in</strong>k >4 alcoholic beverages<br />
per day or >16 per week<br />
Women who dr<strong>in</strong>k >3 alcoholic<br />
beverages per day or >12 per week<br />
Persons who admit to recreational<br />
use of marijuana or hashish <strong>in</strong> previous<br />
year<br />
Persons who are